Cochrane Review Group
Cystic Fibrosis and Genetic Disorders
114 systematic reviews in Cystic Fibrosis and Genetic Disorders ask 2,280 questions. 37.5% have no studies to answer them, 24.1% rest on very low certainty evidence and 13.8% reach moderate or high certainty.
Reviews
114
Questions
2,280
current versions
No studies
37.5%
Moderate or high
13.8%
No studies 856 · 37.5%Ungraded 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin Adverse events · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin Hospitalisations · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin New acquisition of CF pathogens: PA · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin Need for additional antibiotics · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin QoL · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulised azithromycin vs oral azithromycin FEV1 % predicted: mean change from baseline · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | 1 study · 45 participants | Very low |
Summary of findings ‐ nebulised azithromycin vs oral azithromycin Pulmonary exacerbations: time to next exacerbation · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulised azithromycin vs oral azithromycin Adverse events: number of treatment‐related adverse events · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | 1 study · 45 participants | Very low |
Summary of findings ‐ nebulised azithromycin vs oral azithromycin Hospitalisations · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulised azithromycin vs oral azithromycin New acquisition of CF pathogens: PA (mean change in PA count (log10 PA CFU/g sputum)) · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | 1 study · 45 participants | Very low |
Summary of findings ‐ nebulised azithromycin vs oral azithromycin Need for additional antibiotics · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulised azithromycin vs oral azithromycin QoL: change in PEDsQL‐4 scale · children with cystic fibrosis Macrolide antibiotics (including azithromycin) for cystic fibrosis (2024) · Cochrane | no estimate extracted | 1 study · 45 participants | Very low |
Reviews 114
Oral calorie supplements for cystic fibrosis
CochraneSoF table
7 questions
Deferasirox for managing iron overload in people with thalassaemia
CochraneSoF table
49 questions
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
CochraneSoF table
12 questions
Enzyme replacement therapy for infantile‐onset Pompe disease
CochraneSoF table
7 questions
Long‐acting inhaled bronchodilators for cystic fibrosis
CochraneSoF table
11 questions
Enzyme replacement therapy for Anderson‐Fabry disease
CochraneSoF table
18 questions
Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its related complications
CochraneSoF table
8 questions
Exercise for haemophilia
CochraneSoF table
25 questions
Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias
CochraneSoF table
9 questions
Oral protein calorie supplementation for children with chronic disease
CochraneSoF table
7 questions
Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis
CochraneSoF table
11 questions
Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease
CochraneSoF table
18 questions
Deferasirox for managing transfusional iron overload in people with sickle cell disease
CochraneSoF table
7 questions
Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B
CochraneSoF table
5 questions